Cargando…

Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease

BACKGROUND: Inflammatory reaction is an essential factor in the occurrence, development and prognosis of femoropopliteal disease (FPD). The ratio of platelets to lymphocytes (PLR) is a new indicator reflecting platelet aggregation and burden of systemic inflammation. Our study is to explore the asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhen, Yanhua, Chang, Zhihui, Liu, Zhaoyu, Zheng, Jiahe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950933/ https://www.ncbi.nlm.nih.gov/pubmed/31918662 http://dx.doi.org/10.1186/s12872-019-01314-1

Ejemplares similares

Vessel Patency and Associated Factors of Drug‐Coated Balloon for Femoropopliteal Lesion
por: Soga, Yoshimitsu, et al.
Publicado: (2022)

Paclitaxel-Coated Balloon Angioplasty of Venous Stenoses in Native Dialysis Fistulas: Primary and Secondary Patencies at 6 and 12 Months
por: Verbeeck, Nicolas, et al.
Publicado: (2016)

Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study
por: Wang, Zhihong, et al.
Publicado: (2022)

Impact of Peak Systolic Velocity Ratio after Drug-Coated Balloon for Femoropopliteal Disease: Three-Month Serial Observation Vessel Echo Study
por: Kawasaki, Daizo, et al.
Publicado: (2022)

Propensity score-matched analysis of six-month outcomes of paclitaxel-coated balloons combined with UltraScore balloons versus conventional scoring balloons for femoropopliteal lesions
por: Haraguchi, Takuya, et al.
Publicado: (2023)

Three-Year Patency Results following Endovascular Transvenous Femoropopliteal Bypass
por: Rumba, Roberts, et al.
Publicado: (2023)

Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics
por: Du, Xin, et al.
Publicado: (2019)

Clinical Outcomes of Atherectomy Plus Drug-coated Balloon Versus Drug-coated Balloon Alone in the Treatment of Femoropopliteal Artery Disease
por: Cha, Jung-Joon, et al.
Publicado: (2021)

Association between post-balloon angioplasty dissection and primary patency in complex femoropopliteal artery disease: 2-year clinical outcomes of the AcoArt I trial
por: Ren, Hao, et al.
Publicado: (2021)

Impact of Chocolate percutaneous transluminal angioplasty balloon on vessel preparation in drug-coated balloon angioplasty for femoropopliteal lesion
por: Shirai, Shigemitsu, et al.
Publicado: (2022)

Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies
por: Krishnan, Prakash, et al.
Publicado: (2017)

Efficacy of Super Slow Inflation as Lesion Preparation for Drug-Coated Balloons in Femoropopliteal Lesions
por: Sugihara, Makoto, et al.
Publicado: (2020)

Improving the Outcomes of Complex Lesions of the Femoropopliteal Artery Using Atherectomy and Drug Coated Balloon
por: Kim, Sangmin
Publicado: (2022)

Drug-Coated Balloon for the Treatment of Femoropopliteal Tosaka Class III In-stent Restenosis Lesions
por: Zhang, Bihui, et al.
Publicado: (2021)

Intravascular Lithotripsy and Drug-Coated Balloon Angioplasty for Severely Calcified Femoropopliteal Arterial Disease
por: Stavroulakis, Konstantinos, et al.
Publicado: (2022)

Paclitaxel-coated balloons angioplasties for extra-long femoropopliteal artery atherosclerotic lesions (> 30 cm):12 months outcomes from a single center
por: Pan, Tao, et al.
Publicado: (2022)

Emerging Stent and Balloon Technologies in the Femoropopliteal Arteries
por: Pastromas, Georgios, et al.
Publicado: (2014)

Debulking plus drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal Tosaka III in-stent restenosis lesions
por: Li, Liqiang, et al.
Publicado: (2022)

Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency()
por: Marples, Rory, et al.
Publicado: (2021)

Feasibility and Clinical Outcomes of Peripheral Drug-Coated Balloon in High-Risk Patients with Femoropopliteal Disease
por: Jang, Shih-Jung, et al.
Publicado: (2015)

Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions
por: Horie, Kazunori, et al.
Publicado: (2021)

Drug-coated balloon angioplasty versus balloon angioplasty for treating patients with in-stent restenosis in the femoropopliteal artery: A meta-analysis
por: Cao, Shaobo, et al.
Publicado: (2021)

Twelve-Month Results From the First-in-China Prospective, Multi-Center, Randomized, Controlled Study of the FREEWAY Paclitaxel-Coated Balloon for Femoropopliteal Treatment
por: Zhang, Bihui, et al.
Publicado: (2021)

Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease
por: Ren, Hao, et al.
Publicado: (2021)

Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
por: Hanna, Jonathan, et al.
Publicado: (2023)

Impact of number of run-off vessels on interwoven nitinol mesh stents patency in the femoropopliteal segment
por: Rigatelli, Gianluca, et al.
Publicado: (2020)

The Predictive Role of NLR and PLR in Outcome and Patency of Lower Limb Revascularization in Patients with Femoropopliteal Disease
por: Russu, Eliza, et al.
Publicado: (2022)

Novel predictors of infarct-related artery patency for ST-segment elevation myocardial infarction: Platelet-to-lymphocyte ratio, uric acid, and neutrophil-to-lymphocyte ratio
por: Acet, Halit, et al.
Publicado: (2016)

Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Global Study
por: Ansel, Gary M., et al.
Publicado: (2018)

Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort
por: Torsello, Giovanni, et al.
Publicado: (2020)

Drug-Coated Balloon Angioplasty and Debulking for the Treatment of Femoropopliteal In-Stent Restenosis: A Systematic Review and Meta-Analysis
por: Tong, Zhu, et al.
Publicado: (2020)

Excimer laser atherectomy combined with drug-coated balloon angioplasty for the treatment of chronic obstructive femoropopliteal arterial disease
por: Liu, Hui, et al.
Publicado: (2020)

Multiple drug-coated balloons can be used effectively for peripheral arterial disease including long femoropopliteal lesions
por: Chu, Wongong, et al.
Publicado: (2021)

Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study
por: Zeller, Thomas, et al.
Publicado: (2017)

First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease
por: Mwipatayi, Bibombe Patrice, et al.
Publicado: (2017)

One-year results of drug-coated balloons for long and occlusive Femoropopliteal artery disease: a single-arm trial
por: Lai, Zhichao, et al.
Publicado: (2020)

A Multicenter Randomized Trial Assessing ZENFlow Carrier-Free Drug-Coated Balloon for the Treatment of Femoropopliteal Artery Lesions
por: Ni, Leng, et al.
Publicado: (2022)

BioMimics 3D Stent in Femoropopliteal Lesions: 3-Year Outcomes with Propensity Matching for Drug-Coated Balloons
por: Piorkowski, Michael, et al.
Publicado: (2023)

Stellarex drug‐coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12‐Month results from a prospective, multicenter, single‐arm study
por: Schroë, Herman, et al.
Publicado: (2017)

Intercondylar Route of Prosthetic Infragenicular Femoropopliteal Bypass Has Better Primary, Assisted, and Secondary Patency but Not Limb Salvage Rate Compared to the Medial Route
por: Grus, Tomas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mf9nu7oq737a9j14ig4k05jls4